Filtered By:
Specialty: Drugs & Pharmacology
Management: Medicare

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 32 results found since Jan 2013.

Unintended Consequences of Increased Out-of-Pocket Costs During Medicare Coverage Gap on Anticoagulant Discontinuation and Stroke
ConclusionIncreased OOP costs during Medicare coverage gap were associated with higher risk of DOAC discontinuation, which in turn was associated with higher risk of stroke and SE among beneficiaries with NVAF.
Source: Advances in Therapy - August 11, 2023 Category: Drugs & Pharmacology Source Type: research

FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin
[05-13-2014] In its ongoing review of the blood thinner Pradaxa (dabigatran), the U.S. Food and Drug Administration (FDA) recently completed a new study in Medicare patients comparing Pradaxa to an older blood thinner, warfarin, for risk of ischemic or clot-related stroke, bleeding in the brain, major gastrointestinal (GI) bleeding, myocardial infarction (MI), and death.
Source: FDA Center for Drug Evaluation and Research - What's New - February 26, 2018 Category: Drugs & Pharmacology Source Type: news

Comparison of real-world outcomes in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulant agents or warfarin.
Conclusion: The results of the study indicated that patients on DOACs had lower rates of ischemic stroke, hemorrhagic stroke, SE, and composite outcome of stroke or SE compared with patients on warfarin. No significant differences in bleeding rates between the DOAC and warfarin groups were observed, while total cost of care was lower in the DOAC group. PMID: 30698654 [PubMed - as supplied by publisher]
Source: American Journal of Health-System Pharmacy : AJHP - January 29, 2019 Category: Drugs & Pharmacology Authors: Datar M, Crivera C, Rozjabek H, Abbass IM, Xu Y, Pasquale MK, Schein JR, Andrews GA Tags: Am J Health Syst Pharm Source Type: research

Bleeding as an Outcome Among Patients With Nonvalvular Atrial Fibrillation in a Large Managed Care Population.
CONCLUSIONS: Bleeding incidence among patients with NVAF in a real-world setting was high and increased with greater stroke and bleeding risk scores. Health care costs for patients with major bleeding events were elevated. All rights reserved. PMID: 24075151 [PubMed - as supplied by publisher]
Source: Clinical Therapeutics - September 25, 2013 Category: Drugs & Pharmacology Authors: Deitelzweig SB, Pinsky B, Buysman E, Lacey M, Makenbaeva D, Wiederkehr D, Graham J Tags: Clin Ther Source Type: research

Development of algorithms for identifying fatal cardiovascular disease in Medicare claims
ConclusionThe claims‐based algorithms developed to discriminate fatal CVD events from other causes of death performed better than the method of using hospital discharge diagnosis codes.
Source: Pharmacoepidemiology and Drug Safety - March 14, 2018 Category: Drugs & Pharmacology Authors: Fenglong Xie, Lisandro D. Colantonio, Jeffrey R. Curtis, Meredith L. Kilgore, Emily B. Levitan, Keri L. Monda, Monika M. Safford, Ben Taylor, Mark Woodward, Paul Muntner Tags: ORIGINAL REPORT Source Type: research

Patient Diversity and Population Health-Related Cardiovascular Outcomes Associated with Warfarin Use in Atrial Fibrillation: An Analysis Using Administrative Claims Data
ConclusionsDifferences in population health metrics across race/ethnicity and gender exist in AF. Across all metrics, Blacks had comparatively worse outcomes. Patient diversity should be a focus for future investigations in AF to improve outcomes in the whole population.FundingNational Minority Quality Forum.
Source: Advances in Therapy - September 15, 2018 Category: Drugs & Pharmacology Source Type: research

National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of medicare part d beneficiaries.
CONCLUSIONS: Warfarin use rates vary by patient characteristics and region, with higher rates among residents of the Midwest and among patients seen by cardiologists and PCPs. Preventing stroke-related disability in AF requires implementation of evidence-based initiatives to increase warfarin use. PMID: 23324508 [PubMed - in process]
Source: The Annals of Pharmacotherapy - January 1, 2013 Category: Drugs & Pharmacology Authors: Raji MA, Lowery M, Lin YL, Kuo YF, Baillargeon J, Goodwin JS Tags: Ann Pharmacother Source Type: research

Cardiovascular and mortality risks in older Medicare patients treated with varenicline or bupropion for smoking cessation: an observational cohort study
ConclusionCardiovascular and mortality risks were not increased in older patients treated with varenicline compared with bupropion for smoking cessation. A potential increase in the risk of stroke with varenicline could not be excluded. Treatment persistence with either drug was low. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.
Source: Pharmacoepidemiology and Drug Safety - July 5, 2014 Category: Drugs & Pharmacology Authors: David J. Graham, Kunthel By, Stephen McKean, Andrew Mosholder, Cynthia Kornegay, Judith A. Racoosin, Jessica Young, Mark Levenson, Thomas E. MaCurdy, Chris Worrall, Jeffrey A. Kelman Tags: Original Report Source Type: research

Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
ConclusionPatients with NVAF and  ≥ 6 comorbid conditions had significantly different risks for stroke/SE and MB when comparing DOACs to DOACs, and different healthcare expenses. This study's results may be useful for evaluating the risk–benefit ratio of DOAC use in patients with NVAF and multimorbidity.
Source: Advances in Therapy - December 17, 2022 Category: Drugs & Pharmacology Source Type: research

Predicting treatment effects of a new-to-market drug in clinical practice based on phase III randomized trial results
Clin Pharmacol Ther. 2023 Jun 26. doi: 10.1002/cpt.2983. Online ahead of print.ABSTRACTTrial results may not be generalizable to target populations treated in clinical practice with different distributions of baseline characteristics that modify the treatment effect. We used outcome models developed with trial data to predict treatment effects in Medicare populations. We used data from the Randomized Evaluation of Long-Term Anticoagulation Therapy trial (RE-LY), which investigated the effect of dabigatran vs. warfarin on stroke or systemic embolism (stroke/SE) among patients with atrial fibrillation. We developed outcome m...
Source: Clinical Pharmacology and Therapeutics - June 27, 2023 Category: Drugs & Pharmacology Authors: HoJin Shin Shirley V Wang Dae Hyun Kim Ethan Alt Mufaddal Mahesri Lily G Bessette Sebastian Schneeweiss Mehdi Najafzadeh Source Type: research

Appropriate baseline laboratory testing following ACEI or ARB initiation by Medicare FFS beneficiaries
ConclusionsAppropriate monitoring could be improved for African‐American beneficiaries and beneficiaries with a history of stroke or Alzheimer's disease and related disorders initiating ACE inhibitors or ARBs. Copyright © 2016 John Wiley & Sons, Ltd.
Source: Pharmacoepidemiology and Drug Safety - March 1, 2016 Category: Drugs & Pharmacology Authors: Matthew L. Maciejewski, Bradley G. Hammill, Laura G. Qualls, Susan N. Hastings, Virginia Wang, Lesley H. Curtis Tags: Original Report Source Type: research

Use of oral anticoagulants among individuals with cancer and atrial fibrillation in the united states, 2010 ‐2016
ConclusionsNearly 7 out of 10 patients with cancer and NVAF did not receive anticoagulation. Use of DOACs increased from 2010 to 2016, with a corresponding decline in warfarin use. DOACs are used less than warfarin among those at higher risk of stroke.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 3, 2022 Category: Drugs & Pharmacology Authors: Shirin Ardeshirrouhanifard, Huijun An, Ravi K. Goyal, Mukaila A. Raji, Jodi B. Segal, G. Caleb Alexander, Hemalkumar B. Mehta Tags: RESEARCH ARTICLE Source Type: research

Use of oral anticoagulants among individuals with cancer and atrial fibrillation in the United States, 2010 –2016
ConclusionsNearly 7 out of 10 patients with cancer and NVAF did not receive anticoagulation. Use of DOACs increased from 2010 to 2016, with a corresponding decline in warfarin use. DOACs are used less than warfarin among those at higher risk of stroke.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 6, 2022 Category: Drugs & Pharmacology Authors: Shirin Ardeshirrouhanifard, Huijun An, Ravi K. Goyal, Mukaila A. Raji, Jodi B. Segal, G. Caleb Alexander, Hemalkumar B. Mehta Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Cardiovascular and mortality risk in elderly Medicare beneficiaries treated with olmesartan versus other angiotensin receptor blockers
ConclusionsHigh‐dose olmesartan was associated with an increased risk of death in diabetic patients treated for 6 months or longer and with a reduced risk of death in nondiabetic patients, when compared with use of other ARBs. This latter effect was probably because of selective prescribing of olmesartan to healthier patients, although effect modification cannot be excluded. Published 2013. This article is a U. S. Government work and is in the public domain in the USA.
Source: Pharmacoepidemiology and Drug Safety - October 1, 2013 Category: Drugs & Pharmacology Authors: David J. Graham, Esther H. Zhou, Stephen McKean, Mark Levenson, Katlyn Calia, Kate Gelperin, Xiao Ding, Thomas E. MaCurdy, Chris Worrall, Jeffrey A. Kelman Tags: Original Report Source Type: research